Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 21 - 30 of about 143   

Articles published

GSK 1,634.56 -4.94 (-0.30%)
price chart
Bank of America ML Didn't Change HIV Estimates for GlaxoSmithKline plc (ADR) (GSK)
Gilead reported PII data for bictegravir (potential competitor to GlaxoSmithKline plc's (ADR) (NYSE:GSK) integrase inhibitor Tivicay), at the CROI HIV conference, that, as expected shows similarly strong efficacy to GlaxoSmithKline plc's (ADR) (NYSE ...
GlaxoSmithKline Performance Continues, but Generic Competition May Finally ...  Motley Fool
Calculating the intrinsic value of GlaxoSmithKline plc (LSE:GSK)
How far off is GlaxoSmithKline (LSE:GSK) to its intrinsic value? I am going to take a look now by taking the expected future cash flows and discounted them to the value today.
GSK – GlaxoSmithKline plc: Final Results
Respiratory sales in 2016 increased 2% to �6,510 million, reflecting the continuing transition of the Respiratory portfolio to newer products.
Will Smith & Nephew plc Surge Past GlaxoSmithKline plc, AstraZeneca plc And ...
In the three months, shares in Smith & Nephew have outperformed healthcare stocks such as GlaxoSmithKline plc (LON:GSK) (LSE:GSK.
Large Outflow of Money Witnessed in GlaxoSmithKline PLC
GlaxoSmithKline PLC (GSK) traded on a positive note gaining 0.27 points or 0.67% to be valued at $40.29 per share. Intraday, the shares aggregated $21.52 million in upticks but saw an exodus of $26.9 million in downticks.
ROI of GlaxoSmithKline plc (NYSE:GSK) stands at 8.6  TopChronicle
Most Recent analysts Ratings: GlaxoSmithKline plc (NYSE:GSK)  News Oracle
Does AstraZeneca plc Have More Investment Appeal Than GlaxoSmithKline plc ...
That's behind the performance of healthcare stocks such as GlaxoSmithKline plc (LON:GSK) (LSE:GSK.L), Shire PLC (LON:SHP) LSE:SHP.
The GlaxoSmithKline plc (GSK) Receives Buy Rating from Jefferies Group LLC
GlaxoSmithKline plc (LON:GSK)'s stock had its “buy” rating reaffirmed by analysts at Jefferies Group LLC in a note issued to investors on Monday.
JP Morgan Chase & Co Reiterates Neutral Rating for GlaxoSmithKline PLC (GSK)  Sports Perspectives
GlaxoSmithKline plc (GSK) Rating Reiterated by Liberum Capital  Chaffey Breeze
What Analysts Report Shows About GlaxoSmithKline PLC (NYSE:GSK)?
GlaxoSmithKline PLC (NYSE:GSK) has raised a target price of $48.5 from analysts. It is subject to 2 estimates. On 1-5 scale, the equity ranked 1.86 based on 2 calls.
GlaxoSmithKline PLC (GSK) stock down despite upgrade at Zacks Investment Research
GlaxoSmithKline PLC (NYSE: GSK) shares fell back in value on Tuesday February 7 on slower trade volume than normal after a number of analysts weighed in on the investing value of the stock with a upgraded rating.
Analysts Set GlaxoSmithKline PLC (GSK) Target Price at $48.33  Sports Perspectives
GlaxoSmithKline PLC (NYSE:GSK) EPS Projection Set At $0.74  Transcript Daily
GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
GlaxoSmithKline plc GSK is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.